Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding
Others
Ratios

NewAmsterdam Pharma (NAMSW) Revenue (2023 - 2025)

Historic Revenue for NewAmsterdam Pharma (NAMSW) over the last 3 years, with Q3 2025 value amounting to $348000.0.

  • NewAmsterdam Pharma's Revenue fell 9880.46% to $348000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $35.2 million, marking a year-over-year increase of 490.86%. This contributed to the annual value of $45.6 million for FY2024, which is 22337.12% up from last year.
  • As of Q3 2025, NewAmsterdam Pharma's Revenue stood at $348000.0, which was down 9880.46% from $19.1 million recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma's Revenue ranged from a high of $29.1 million in Q3 2024 and a low of $348000.0 during Q3 2025
  • Over the past 3 years, NewAmsterdam Pharma's median Revenue value was $2.9 million (recorded in 2023), while the average stood at $7.5 million.
  • Its Revenue has fluctuated over the past 5 years, first surged by 149053.55% in 2024, then crashed by 9880.46% in 2025.
  • Over the past 3 years, NewAmsterdam Pharma's Revenue (Quarter) stood at $803000.0 in 2023, then soared by 1490.54% to $12.8 million in 2024, then plummeted by 97.28% to $348000.0 in 2025.
  • Its Revenue was $348000.0 in Q3 2025, compared to $19.1 million in Q2 2025 and $3.0 million in Q1 2025.